more than placebo for two years in patients with immunoglobulin A (IgA) nephropathy.
targeted-release budesonide (Nefecon) treatment reduces estimated glomerular filtration rate
. 14 in The Lancet found that nine months of targeted-release budesonide
Richard Lafayette, M.D., from Stanford University in California
randomized study in persons with primary IgA nephropathy
for nine months followed by a 15-month observational follow-up.
The study found that budesonide significantly improved eGFR over two years compared to placebo
There were no treatment-related fatalities.